Dishman Carbogen Amcis Ltd

- There is no mention of any immediate or planned new fundraising through debt or equity in the transcript. - Current debt stands at about CHF 163 million as of March 31, 2024, with no significant increase expected going forward. - The company is generating free cash flow starting FY'25, which should help reduce net debt over the next 2-3 years. - Discussions are ongoing with banks regarding covenant waivers and possibly more favorable loan terms to reduce interest cost. - No specific plans for raising fresh equity or debt were indicated; focus is on optimizing existing financial structure and operational cash flow generation.

- Most major capex programs have been completed, including those in France, Switzerland (co-investment projects), and Indian sites (Bavla and Naroda). - Current CWIP (~INR500 crores) mainly includes capital expenditure for the second manufacturing line in France (expected operational during FY '25) and some digital transformation projects. - FY '25 capex guidance is around $25-30 million, with approximately $18 million for maintenance capex and the remainder for completing digital transformation and some additional capex in Bavla and Naroda. - No major new capex programs are planned beyond routine maintenance and a water purification plant in Bavla. - Digital transformation is ongoing, including implementation of SAP and other digital tools to improve productivity. - All capex is aimed at supporting growth, regulatory clearances, and operational improvements across sites.

- India CRAMS business expected to ramp up significantly post regulatory clearances, targeting around INR350 crores revenue in FY '25, moving towards INR400-500 crores by FY '26-27. - Overall CRAMS revenue (including French entity) projected to grow at 14-15% annually. - Swiss entity expected to post 8-10% revenue growth in FY '25. - UK entity projected to rebound strongly with 40-50% growth in FY '25 due to lower base last year. - French facility, now operational after resolving technical issues, anticipated to ramp up revenue beyond the current ~$14 million in FY '25, contributing substantially going forward. - Total consolidated revenue growth target for FY '25 is around 10-12%. - Ramp-up in second half of FY '25 expected to be faster than first half, with better quarterly performances post Q2. - Innovation and new projects (e.g., vitamin D products) expected to contribute to revenue growth starting FY '26 onwards.

- Financial Year (FY) 2025 is expected to be significantly better than FY 2024 with normalization post France issues. - Revenue growth guidance for FY 2025: 10-12% consolidated growth, driven by ramp-up in India and Bangladesh businesses, and recovery in UK and France. - EBITDA margin target for FY 2025: 18-20%, improving due to reduced exceptional costs and raw material cost controls, especially in the Netherlands. - Positive cash flow expected from FY 2025 onwards, with free cash flow around INR 400-500 crores. - Net profit after tax (PAT) is expected to turn positive from FY 2026, considering a recurring goodwill write-off of INR 45 crores per annum. - EBITDA losses in France expected to reduce from INR 100 crores (FY 24) to INR 35-40 crores (FY 25) and break even by FY 26. - Capex for FY 25 guided at USD 25-30 million, mainly maintenance and digital transformation. - Management aims for mid-to-high teens percentage revenue growth in CRAMS businesses in FY 25-26.

- The company currently has development orders in excess of $140 million (page 17). - There are already orders in hand for the French facility, with an additional $90 million of Requests for Proposal (RFP) out (page 27). - The ramp-up of the India and Bangladesh businesses is expected to contribute significant order growth in H2 FY '25 (page 28). - New customers are coming to the Bavla site post regulatory clearances, indicating increasing orders (page 20). - Positive outlook on the Swiss entity's order book with expected consistent growth of 8-10% in revenues (page 18). - Overall, the company expects much higher growth in the second half of FY '25 driven by order inflow and operational normalization (page 28).